EpiPen’s pricing debacle and its impact on patients, insurers
A firestorm erupted this week in response to the pharmaceutical company Mylan’s sharp increase in the price of its EpiPen, a life-saving treatment for severe allergic reactions. The company quickly backtracked, announcing a rebate plan. Here, three Northeastern faculty members—pharmacist Tayla Rose, healthcare finance expert Steven Pizer, and health policy researcher Gary Young—explain the clinical, economic, and policy implications of the controversy.
